However, in subsequent studies, IHC detection of stromal or tumor HGF in pre-therapy melanoma specimens failed to predict patient response to BRAF inhibitors [63]; therefore, the power of HGF as a negative predictor of response to BRAF-targeted therapies needs to be further investigated. The gene discussed is HGF; the disease is neoplasm.